Expert Forum on Antimicrobial Resistance

05 Sep 2018

Location: Rüschlikon/Zurich, Switzerland

About the event

In 2014, Lord O’Neill published a review commissioned by the UK government that described how by 2050, 10 million people around the world will die every year due to superbug infections. The term "superbug" refers to bacteria, which are resistant to antibiotics. The medical breakthroughs of the last century could be lost through the spread of epidemics, or even pandemics, meaning that previously curable infections may become untreatable, Large scale deaths, or lifetime impairment, could result. The pipeline for new antibiotics is almost dry. This development can change the expectations on mortality trends for the insurance industry. Consequently, the industry is monitoring and modeling potential mortality shocks. So far the focus has been on influenza but the model is useful for other epidemics: including superbug triggered pandemics. Work in the field has already yielded new insurance solutions. In collaboration with the World Bank and WHO, the launch of the Pandemic Emergency Financing Facility was possible. It helps to mobilize funds quickly during a disease outbreak such as Ebola in West Africa, instead of having first a donor conference to secure funding.

Modelling and insuring risks is not enough. We must battle antimicrobial resistance more proactively.

We invited you to join us for an Expert Workshop at the Swiss Re Institute, to discuss with leading industry specialists how the global insurance system can contribute to countering the impact of antimicrobial resistance (AMR). A key discussion topic for Swiss Re managers attending the workshop was how to develop risk management measures to avoid the occurrence of outbreaks. Further steps that were considered are how to use insurance to reduce the cost and impact of epidemics. The Expert Workshop was followed by a public risk talk to address the same issue.

Presentations

12.00

Welcome lunch and coffee

13.20

Welcome and introduction
Urs Widmer, Medical Officer, Swiss Re

Session Drivers of antimicrobial resistance

13.30

Global trends in antimicrobial use in food animals
Thomas van Boeckel, Theoretical Biology, ETH Zurich

13.45

Use of Antibiotics in Livestock and Human Health Concerns
Cedric Müntener, Institute of Veterinary Pharmacology and Toxicology, University of Zurich

14.00

Identifying the drivers of antimicrobial resistance
Roger Kouyos, Department of Infectious Diseases, University of Zurich

14.15

Workshops Series I

Round 1 starts at 14:15
Round 2 starts at 14:45

Session 1:  AMR surveillance strategies – Magnitude of global threat and expected mortality or liability claims
Experts: Stephan Harbarth, Jennifer Rohn
Moderators: Jürg A. Schmid,  Urs Widmer

Session 2: Using antibiotics wisely in a One Health world – how can insurance incentivize?
Experts: Thomas van Boeckel, Cedric Müntener
Moderators: Petra Winter, Ramiro Dip, Rainer Egloff

Session 3: Modelling AMR, what is a reinsurer's mortality exposure?
Experts: Roger Kouyos
Moderators: Yommy Chiu, Manuel Villegas Caballero

15.15

Coffee break

Session

Preventing the "Post-Antibiotic Apocalypse"

15.30

Strategies to battle AMR - New funding mechanisms and paradigm shifts
Marie Petit, BEAM Alliance

15.40

Case study: Murepavadin is a new antibiotic class in the pipeline to treat resistant Pseudomonas infections
Michael Altorfer, CEO Swiss Biotech Association

15.50

How to reinvigorate the current R&D pipeline
Peter Beyer, Senior Advisor, World Health Organization (WHO)

16.00

Fostering investment in AMR innovation
Christoph Spennemann, Intellectual Property Unit, Division on Investment & Enterprise, UNCTAD, Geneva

16.10

Workshops Series II

Session 4: Cost Sharing in Insurance Coverage for antibiotic-resistant infections, an example of Precision Medicine
Experts:  Michael Altorfer, Peter Beyer
Moderators: Yommy Chiu, Rainer Egloff

Session 5: Alternative business model options for antibiotics development – ideas from insurers?
Expert: Christoph Spennemann, Marie Petit
Moderators: Bernd Wilke, Petra Winter

Session 6: Scientific innovation in antibiotic drug discovery - Examples of new platforms and novel compounds
Expert: Jennifer Rohn, Stephan Harbarth
Moderators: Ramiro Dip, Urs Widmer

16.40

Panel Discussion and Closing remarks
Ramiro Dip and Urs Widmer

Pannelists:
Michael Altorfer, CEO Swiss Biotech Association
Thomas van Boeckel, Theoretical Biology, ETH Zurich
Roger Kouyos, Department of Infectious Diseases, University of Zurich
Cedric Müntener, Institute of Veterinary Pharmacology and Toxicology, University of Zurich
Marie Petit, BEAM Alliance
Christoph Spennemann, Intellectual Property Unit, Division on Investment & Enterprise, UNCTAD, Geneva
Peter Beyer, Senior Advisor, World Health Organization (WHO)

17.15

End of workshop

Speakers

Gallery

Photos by: Fredi Lienhardt